What it's for (Indications)
- Diflucortolone + chlorquinaldol combination is indicated for the treatment of inflammatory skin conditions that are responsive to topical corticosteroids, particularly when complicated by bacterial or fungal infections, or when there is a significant risk of such secondary infections.
- This includes various forms of eczema (e.
- g.
- , atopic dermatitis, contact dermatitis, seborrheic dermatitis), psoriasis (excluding extensive plaque psoriasis), lichen planus, intertrigo, and other corticosteroid-responsive dermatoses where the presence or potential for sensitive bacterial or fungal organisms necessitates an antimicrobial component.
- Its dual action aims to reduce inflammation and pruritus while concurrently targeting microbial pathogens.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | This medication should be applied thinly to the affected skin areas once or twice daily, as directed by a healthcare professional. The precise frequency and duration of treatment are dependent upon the severity and nature of the dermatosis, the patient's response to therapy, and the specific area being treated. Due to the potent corticosteroid component (diflucortolone), prolonged use, particularly on extensive body surface areas, facial skin, or intertriginous regions, should be avoided and generally not exceed 2-4 weeks. Occlusive dressings are typically not recommended unless specifically advised by a physician due to the potential for increased systemic absorption and local adverse effects. Regular reassessment of the patient's condition is crucial to determine the continued need for treatment. |
Safety & Warnings
Common Side Effects
- Topical application of diflucortolone + chlorquinaldol may lead to a range of local and, less commonly, systemic adverse effects.
- Common local side effects associated with the corticosteroid component include skin atrophy (thinning), striae (stretch marks), telangiectasias (spider veins), purpura, hypertrichosis (excessive hair growth), acneiform eruptions, perioral dermatitis, contact dermatitis, and hypopigmentation.
- The chlorquinaldol component may cause local irritation, burning, itching, or allergic sensitization.
- Systemic side effects, though rare with appropriate topical use, can occur, especially with extensive application, prolonged duration, occlusive dressings, or in pediatric patients.
- These may include reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
- Should any severe or persistent adverse reactions occur, discontinue use and consult a physician.
Serious Warnings
- Black Box Warning: **Serious Warnings: Adrenal Suppression and Systemic Effects:** Potent topical corticosteroids, such as diflucortolone, particularly when applied to large surface areas, for prolonged durations, under occlusive dressings, or to areas with compromised skin barrier function, can lead to significant systemic absorption. This absorption may result in reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, potentially causing adrenal insufficiency. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria have also been reported. Pediatric patients are particularly vulnerable to systemic toxicity due to their higher skin surface area to body weight ratio and underdeveloped skin barrier. Regular assessment for HPA axis suppression (e.g., ACTH stimulation test) may be necessary, especially with extensive or prolonged use. If HPA axis suppression is noted, gradual withdrawal of the drug, reduction in frequency of application, or substitution with a less potent corticosteroid should be considered. **Increased Risk of Infection and Masking of Symptoms:** While chlorquinaldol provides antimicrobial action, the corticosteroid component can mask the clinical signs of infection, potentially delaying diagnosis and appropriate treatment. Prolonged or inappropriate use may lead to overgrowth of non-susceptible organisms, including fungi and bacteria, or exacerbate existing skin infections. Discontinue treatment if a new infection or worsening of an existing infection develops, and initiate appropriate antifungal or antibacterial therapy. **Local Adverse Reactions and Skin Atrophy:** Prolonged application, particularly on sensitive areas like the face, genitals, and intertriginous zones, can lead to irreversible skin atrophy, striae, telangiectasias, purpura, and bruising. These effects are more pronounced with potent corticosteroids. Use with caution and limit the duration of therapy to minimize these risks. **Not for Ophthalmic Use:** This product is not intended for ophthalmic application. Contact with eyes should be strictly avoided due to the potential for serious ocular adverse events, including glaucoma and cataracts.
- This combination preparation requires cautious use.
- Avoid prolonged application, especially on the face, eyelids, intertriginous areas (e.
- g.
- , armpits, groin), and in children, due to increased susceptibility to systemic absorption and local side effects such as skin atrophy.
- Not for ophthalmic use; contact with eyes can lead to glaucoma or cataracts.
- Corticosteroids can mask signs of infection, and while chlorquinaldol provides antimicrobial coverage, continuous monitoring for progression or new infections is essential.
- If irritation or sensitization develops, discontinue treatment.
- Abrupt cessation of potent corticosteroids after prolonged use may lead to rebound phenomena or worsening of the underlying condition.
- Use during pregnancy and lactation should only be considered if the potential benefit justifies the potential risks to the fetus or infant, and extensive application should be avoided.
- Discontinue if severe irritation, allergic reaction, or signs of HPA axis suppression occur.
How it Works (Mechanism of Action)
Diflucortolone + chlorquinaldol is a combination topical medication designed to address inflammatory dermatoses complicated by microbial infections. Diflucortolone is a highly potent, fluorinated synthetic corticosteroid. Its primary mechanism of action involves binding to glucocorticoid receptors within target cells, leading to complex downstream effects including the inhibition of phospholipase A2 (which reduces the release of arachidonic acid and subsequently the synthesis of prostaglandins and leukotrienes, key mediators of inflammation), stabilization of lysosomal membranes, and inhibition of inflammatory cell migration and activity. These actions result in potent anti-inflammatory, antipruritic, and vasoconstrictive effects. Chlorquinaldol is a halogenated quinoline derivative with broad-spectrum antimicrobial activity. It exhibits bactericidal and fungicidal properties against a range of Gram-positive and some Gram-negative bacteria, as well as dermatophytes and yeasts. Its mechanism involves chelating essential metal ions required for microbial enzyme function, thereby disrupting cellular metabolic processes and potentially damaging microbial cell membranes. The synergistic action of diflucortolone to reduce inflammation and chlorquinaldol to combat infection makes this combination effective for mixed dermatological conditions.
Commercial Brands (Alternatives)
No other brands found for this formula.